First ever clinical testing of hookworm

New global consortium to advance first-ever clinical testing of the human hookworm vaccine in sub-Saharan Africa

Effort holds potential to control disease plaguing nearly 700 million people


The New York Times featured the news of this first ever clinical trial in an article by global health reporter Donald McNeil Jr.


PRESS RELEASE – AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership's (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world's poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

The HOOKVAC consortium will build on the clinical development of a safe and cost-effective hookworm vaccine by conducting clinical Phase I studies that test two previously identified lead candidate antigens, Na-GST-1 and Na-APR-1, in African adults and children. Through previous funding received by the Sabin PDP, Phase I clinical trials for the safety and efficacy of Na-GST-1 are underway in the U.S. and Brazil, and a U.S. clinical trial for Na-APR-1 began earlier this month.

Hookworm primarily infects people living below the global poverty line, particularly pregnant women and children in sub-Saharan Africa, Southeast Asia, and Latin America. Left untreated, hookworm causes internal blood loss leading to iron-deficiency anemia and malnutrition. Hookworm also contributes to physical and cognitive impairment, poor school performance and attendance, and low birth weights.

'The importance of developing a vaccine for hookworm cannot be overstated.  This is a devastating disease in Gabon,' said Dr. Ayola Akim Adegnika, co-director of the Centre de Recherches Medicales de Lambarene of the Albert Schweitzer Hospital in Gabon. 'We are proud to take part in the launch of clinical testing in Gabon. The HOOKVAC consortium is paving the way for an advancement that could greatly improve people's health, stimulate economic growth and give rise to other tools to control and eliminate parasitic diseases in Africa and around the world.'

Under this grant, European small-and medium-sized enterprises (SMEs) are enhancing global understanding of vaccines for neglected tropical diseases (NTDs) through research and development partnerships that pave the way for an optimized manufacturing process and vaccine formulation.

'The European Commission is proud to support the critical work of the consortium for the development of a human hookworm vaccine,' said Ruxandra Draghia-Akli, MD, PhD, director of the Health Directorate at the Research DG of the European Commission. 'Ultimately, we hope that the knowledge, innovations and research expertise resulting from this global collaboration will accelerate the development of the world's first, effective hookworm vaccine and encourage additional European SME partnerships to explore vaccines for NTDs.'

For over a decade, the Sabin PDP, which is based at Texas Children's Hospital and Baylor College of Medicine in Houston, Texas, has been working on a human hookworm vaccine with the support of the Bill & Melinda Gates Foundation, Dutch Ministry of Foreign Affairs and Brazilian Ministry of Health. A hookworm vaccine has the potential to dramatically improve the health, economic, and social landscape in countries with high burdens of hookworm disease. As sponsor of the vaccine, the Sabin PDP will contribute to the HOOKVAC consortium by sharing the technology, research findings, and clinical trial results generated in previous studies, and will collaborate on the new clinical studies in Gabon.

'The Sabin PDP is excited to join with new partners from the European Union and Gabon to advance the development of a human hookworm vaccine,' said Dr. Peter Hotez, director of the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development and founding dean of the National School of Tropical Medicine at Baylor College of Medicine. 'By sharing the Sabin PDP's unique expertise in developing vaccines for NTDs with the HOOKVAC consortium, we intend to expand global knowledge of NTDs as well as benefit from the expertise of our new European and African partners to identify cutting edge ways to reduce the global burden of diseases affecting the world's poorest people.'

The HOOKVAC consortium's key European partners include the Amsterdam Institute for Global Health and Development (AIGHD), Academic Medical Center, University of Amsterdam (AMC) and the Leiden University Medical Center (LUMC) in the Netherlands; Q-Biologicals in Belgium; University, Eberhard Karls University, Tuebingen, Institute of Tropical Medicine, Center of Excellence Baden-Wuerttemberg in Germany;  Pharmidex in the UK; and the Centre de Recherches Medicales de Lambarene of the Albert Schweitzer Hospital in Gabon. The key U.S. partners include the Sabin Vaccine Institute, Baylor College of Medicine and The George Washington University.


This press release reflects only the views of AIGHD and the Sabin Vaccine Institute. The European Union is not liable for any use that may be made of the information in this release.




About the Sabin Vaccine Institute

The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent, and cure infectious and neglected tropical diseases.

Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. For more information, please visit


About the Sabin Vaccine Institute Product Development Partnership
The Sabin Vaccine Institute Product Development Partnership (Sabin PDP) focuses on creating safe, effective and low-cost vaccines to prevent human suffering from infectious and neglected tropical diseases that infect more than 1 billion people worldwide. The Sabin PDP collaborates with private, academic and public institutions in low- and middle-income countries (LMIC), the United States and Europe, for preclinical development, vaccine manufacturing and clinical testing.  A complete overview of ongoing projects and partners is available at

Media Contacts:

AIGHD: Remko van Leeuwen, Project Coordinator
T: + 31 6 3978 8139, E:

Sabin Vaccine Institute: Deborah Elson, Communications Officer
T: +1 (202) 621-1691, E: